Singapore is emerging as a key medtech hub in Asia-Pacific as the region shifts from absorbing global medical innovations to creating and exporting its own, according to a report by Bain & Company. The report said Singapore has built a strong medtech ecosystem by combining advanced regulatory standing, clinical translation infrastructure, precision engineering, and end-to-end productisation platforms. This allows the city-state to help turn promising prototypes into globally validated medical devices. Bain said Singapore’s advantage lies in its integrated innovation and productisation hub, which gives companies access to multinational R&D infrastructure, multi-site trial networks, precision engineering manufacturing partners, and an advanced regulatory framework. The ecosystem is supported by platforms such as Singapore Biodesign and Duke-NUS, which train clinicians to identify unmet healthcare needs and turn ideas into investable products.     https://sbr.com.sg/healthcare/news/singapore-emerges-key-hub-in-asia-pacifics-next-medtech-wave (ICE SINGAPORE)

Fonte notizia: Singapore Business Review, 8 July 2026